| Nome |
# |
|
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen., file e27ce0c3-a06e-055e-e053-6605fe0a7873
|
263
|
|
Impact of Cryopreservation of Peripheral Blood Stem Cells (PBSC) in Transplantation from Matched Unrelated Donor (MUD), file f4c211ad-92e1-4d74-8c18-59b7683287d1
|
255
|
|
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe), file e27ce0c3-a8a4-055e-e053-6605fe0a7873
|
247
|
|
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score, file e27ce0c9-76b9-055e-e053-6605fe0a7873
|
242
|
|
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy., file e27ce0c1-f900-055e-e053-6605fe0a7873
|
180
|
|
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis, file e27ce0c3-a279-055e-e053-6605fe0a7873
|
159
|
|
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network, file e27ce0c9-bbd4-055e-e053-6605fe0a7873
|
127
|
|
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma, file e27ce0c3-a074-055e-e053-6605fe0a7873
|
119
|
|
Qualitative and quantitative polymerase chain reaction monitoring minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation ., file e27ce0c5-6196-055e-e053-6605fe0a7873
|
115
|
|
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial, file e27ce0c5-a731-055e-e053-6605fe0a7873
|
110
|
|
JAK-2 inhibitors and allogeneic transplant in myelofibrosis, file e27ce0c3-88f9-055e-e053-6605fe0a7873
|
100
|
|
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs, file e27ce0c7-9ca4-055e-e053-6605fe0a7873
|
82
|
|
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia, file e27ce0c3-a619-055e-e053-6605fe0a7873
|
73
|
|
Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of Infectious Diseases Working Party of the European Bone Marrow Transplantation group, file e27ce0c4-8654-055e-e053-6605fe0a7873
|
62
|
|
Experts’ consensus on the definition and management of high risk multiple myeloma, file 26e92672-6ef5-4443-afb1-dfdbb771b94a
|
52
|
|
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: A pooled analysis of two randomized trials, file e27ce0c8-c8e9-055e-e053-6605fe0a7873
|
41
|
|
Haploidentical transplant after failure of a first allogeneic transplant: a long and winding road, file e27ce0c9-bfc6-055e-e053-6605fe0a7873
|
34
|
|
Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO), file e27ce0c9-409a-055e-e053-6605fe0a7873
|
30
|
|
Screening procedure for SARS-CoV-2 infection combining triage, nasopharyngeal swab and serological test in allogeneic stem cell transplantation recipients undergoing outpatient posttransplant follow-up, file e27ce0c8-e4f5-055e-e053-6605fe0a7873
|
22
|
|
Infliximab treatment for steroid-refractory acute graft-versus-host disease, file e27ce0c5-4a10-055e-e053-6605fe0a7873
|
21
|
|
Pretransplantation 18F-Fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-hodgkin lymphoma undergoing reduced-intensity conditioning follone by allogeneic stem cell transplantation, file e27ce0c5-6195-055e-e053-6605fe0a7873
|
19
|
|
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms, file e27ce0c9-dfb6-055e-e053-6605fe0a7873
|
19
|
|
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients, file e27ce0c8-f375-055e-e053-6605fe0a7873
|
18
|
|
Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide., file e27ce0c5-3a8c-055e-e053-6605fe0a7873
|
17
|
|
The role of monoclonal antibodies in smoldering and newly diagnosed transplant-eligible multiple myeloma, file e27ce0c8-e591-055e-e053-6605fe0a7873
|
17
|
|
Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti, file e27ce0c9-711c-055e-e053-6605fe0a7873
|
15
|
|
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents, file e27ce0c8-bc9e-055e-e053-6605fe0a7873
|
13
|
|
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial, file e27ce0c9-fcbb-055e-e053-6605fe0a7873
|
13
|
|
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 y with Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study, file a0389dfa-755b-4cae-a237-7eb6f0c81bbd
|
12
|
|
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT, file e27ce0c9-6997-055e-e053-6605fe0a7873
|
10
|
|
Risk factors and outcome of c. Difficile infection after hematopoietic stem cell transplantation, file e27ce0c9-bd8d-055e-e053-6605fe0a7873
|
8
|
|
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial, file 765ab2eb-122e-44d4-b3fc-48d10cd3fd4d
|
7
|
|
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial, file 2cfb6c0b-e7bd-4b0a-9434-e18dc2b051a6
|
5
|
|
Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo., file e27ce0c3-c40a-055e-e053-6605fe0a7873
|
5
|
|
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing, file 14071989-4908-4cbc-bfd7-daa739eba5ad
|
4
|
|
The Role of Allogeneic Transplantation in Chronic Myeloid Leukemia in 2023: A Case-Based Concise Review, file 5d38758c-9eef-4c13-abae-66e7067cd840
|
4
|
|
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group, file 939699d0-47de-42d6-9434-e761298c55b8
|
4
|
|
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease, file e27ce0c3-a076-055e-e053-6605fe0a7873
|
4
|
|
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma, file ef091f03-18af-47e9-a35b-225b1b96cee8
|
4
|
|
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study, file 7723ee39-3298-44ec-b72b-96f7690b0790
|
2
|
|
Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome, file e27ce0c1-f0b7-055e-e053-6605fe0a7873
|
2
|
|
High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome., file e27ce0c3-8c44-055e-e053-6605fe0a7873
|
2
|
|
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation, file e27ce0c3-a082-055e-e053-6605fe0a7873
|
2
|
|
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab., file e27ce0c3-a631-055e-e053-6605fe0a7873
|
2
|
|
Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma, file e27ce0c3-b5e3-055e-e053-6605fe0a7873
|
2
|
|
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial., file e27ce0c3-befe-055e-e053-6605fe0a7873
|
2
|
|
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease, file e27ce0c3-c266-055e-e053-6605fe0a7873
|
2
|
|
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy, file e27ce0c9-0093-055e-e053-6605fe0a7873
|
2
|
|
Combined orthotopic heart transplantation followed by autologous stem cell transplantation in a patient with light chain amyloidosis and isolated cardiac involvement, file e27ce0c9-367b-055e-e053-6605fe0a7873
|
2
|
|
Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation, file e27ce0c9-6ef8-055e-e053-6605fe0a7873
|
2
|
|
Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus, file 4eb95126-0619-4e0a-9306-0e3ae1740fed
|
1
|
|
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas, file e27ce0c1-d7af-055e-e053-6605fe0a7873
|
1
|
|
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction before, and consolidation after, double autologous stem cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study., file e27ce0c1-ddb4-055e-e053-6605fe0a7873
|
1
|
|
Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation., file e27ce0c1-e244-055e-e053-6605fe0a7873
|
1
|
|
Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma., file e27ce0c1-e5b4-055e-e053-6605fe0a7873
|
1
|
|
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma, file e27ce0c1-e69f-055e-e053-6605fe0a7873
|
1
|
|
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma., file e27ce0c1-e88b-055e-e053-6605fe0a7873
|
1
|
|
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study., file e27ce0c1-ea7c-055e-e053-6605fe0a7873
|
1
|
|
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia, file e27ce0c1-ef5a-055e-e053-6605fe0a7873
|
1
|
|
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant, file e27ce0c3-87be-055e-e053-6605fe0a7873
|
1
|
|
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia., file e27ce0c3-88a3-055e-e053-6605fe0a7873
|
1
|
|
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability, file e27ce0c3-ae50-055e-e053-6605fe0a7873
|
1
|
|
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?, file e27ce0c4-8288-055e-e053-6605fe0a7873
|
1
|
|
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients., file e27ce0c5-5f52-055e-e053-6605fe0a7873
|
1
|
|
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts, file e27ce0c5-8972-055e-e053-6605fe0a7873
|
1
|
|
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation, file e27ce0c9-283f-055e-e053-6605fe0a7873
|
1
|
|
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation, file e27ce0c9-487c-055e-e053-6605fe0a7873
|
1
|
| Totale |
2.571 |